Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07223593 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
A Phase 3 study of Peripheral Arterial Disease, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,205
- Enrollment target
- 20
- Study locations
NCT07223593 is a Phase 3 study of Peripheral Arterial Disease that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 1,205 participants, below the 4,191-participant average among 79 other Peripheral Arterial Disease trials with a reported enrollment target (71% lower). The trial reports 20 study locations across 9 states.
The verdict
NCT07223593, a Phase 3 study of Peripheral Arterial Disease, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,205 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the effect and safety of orforglipron once daily in participants with Fontaine II peripheral arterial disease (PAD). Participation in the study will last about 58 weeks.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Orforglipron
Study Locations (20)
California
- Valley Clinical Trials, Inc. - Northridge
- The Cardiovascular Center - Redding
- InvivoCure - Van Nuys
- Interventional Cardiology Medical Group - West Hills
Florida
- Lakeview Institute of Clinical Research - Leesburg
- Inpatient Research Clinic - Miami Lakes
- Floridian Clinical Research, LLC - Miami Lakes
- St Johns Center for Clinical Research - Saint Augustine
Arizona
- Mercy Gilbert Medical Center - Gilbert
- Axsendo Clinical Research - Peak Heart & Vascular - Surprise - Surprise
- Del Sol Research Management, LLC - Tucson
Indiana
- ASHA Clinical Research - Munster, LLC - Hammond
- Indiana University Health Methodist Hospital - Indianapolis
- Deaconess Clinic- Gateway - Newburgh
Tennessee
- The Jackson Clinic - Jackson
- East Coast Institute for Research - Jefferson City - Jefferson City
Alabama
- St. Vincent's Birmingham Hospital - Birmingham
Maryland
- Flourish Research - Bowie - Bowie
Michigan
- Arcturus Healthcare , PLC, Troy Internal Medicine Research Division - Troy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,205 participants |
| Start Date | 2025-10-31 |
| Est. Completion | 2028-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07223593
The ClinicalTrials.gov registry entry for NCT07223593 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 1,205 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,191-participant average among 79 other Peripheral Arterial Disease trials with a reported enrollment target (71% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Peripheral Arterial Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07223593 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT07223593 about?
NCT07223593 is a clinical study titled "Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease". The purpose of this study is to evaluate the effect and safety of orforglipron once daily in participants with Fontaine II peripheral arterial disease (PAD). Participation in the study will last about 58 weeks.
What is the current status of trial NCT07223593?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,205 participants. The study started on 2025-10-31. Estimated completion is 2028-06.
What conditions does trial NCT07223593 study?
This clinical trial studies the following conditions: Peripheral Arterial Disease.
What interventions are being tested in trial NCT07223593?
The interventions under investigation include: Placebo (DRUG), Orforglipron (DRUG).
Who is sponsoring clinical trial NCT07223593?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07223593 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peripheral Arterial Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk
RECRUITING · Phase 3
-
SMART Exercise for PAD
RECRUITING · Phase 3
-
SELUTION4BTK Trial
RECRUITING · NA
-
MitoQ Treatment of Claudication: Myofiber and Micro-vessel Pathology
RECRUITING · NA
-
A Real-World Registry of Chronic Wounds and Ulcers
RECRUITING
-
Ramipril Treatment of Claudication: Oxidative Damage and Muscle Fibrosis
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.